Abstract
The development of an effective vaccine against SARS-CoV-2 is urgently needed. We generated SARS-CoV-2 RBD-Fc fusion protein and evaluated its potency to elicit neutralizing antibody response in mice. RBD-Fc elicited a higher neutralizing antibodies titer than RBD as evaluated by a pseudovirus neutralization assay and a live virus based microneutralization assay. Furthermore, RBD-Fc immunized sera better inhibited cell-cell fusion, as evaluated by a quantitative cell-cell fusion assay. The cell-cell fusion assay results correlated well with the virus neutralization potency and could be used for high-throughput screening of large panels of anti-SARS-CoV-2 antibodies and vaccines without the requirement of live virus infection in BSL3 containment. Moreover, the anti-RBD sera did not enhance the pseudotyped SARS-CoV-2 infection of K562 cells. These results demonstrate that Fc fusion can significantly improve the humoral immune response to recombinant RBD immunogen, and suggest that RBD-Fc could serve as a useful component of effective vaccines against SARS-CoV-2.
Keywords:
Cell–cell fusion assay; Receptor-binding domain (RBD); SARS-CoV-2; Subunit vaccine.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiotensin-Converting Enzyme 2
-
Animals
-
Antibodies, Neutralizing / blood
-
Antibodies, Neutralizing / immunology*
-
Antibodies, Viral / blood
-
Antibodies, Viral / immunology*
-
Betacoronavirus / immunology
-
COVID-19
-
COVID-19 Vaccines
-
Cell Fusion
-
Cell Line
-
Coronavirus Infections / immunology
-
Coronavirus Infections / prevention & control*
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
HEK293 Cells
-
High-Throughput Screening Assays / methods
-
Humans
-
Immunity, Humoral / immunology
-
Immunoglobulin Fc Fragments / genetics
-
Immunoglobulin Fc Fragments / immunology*
-
Mice
-
Mice, Inbred BALB C
-
Neutralization Tests
-
Pandemics / prevention & control*
-
Peptidyl-Dipeptidase A / genetics
-
Pneumonia, Viral / prevention & control*
-
Protein Domains / immunology
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology
-
SARS-CoV-2
-
Spike Glycoprotein, Coronavirus / genetics
-
Spike Glycoprotein, Coronavirus / immunology*
-
Vaccines, Subunit / immunology
-
Viral Vaccines / immunology*
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
COVID-19 Vaccines
-
Immunoglobulin Fc Fragments
-
Recombinant Fusion Proteins
-
Spike Glycoprotein, Coronavirus
-
Vaccines, Subunit
-
Viral Vaccines
-
spike protein, SARS-CoV-2
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Ace2 protein, mouse
-
Angiotensin-Converting Enzyme 2